Primer: LianBio (LIAN US) - Aug 2026
Special Situation: Winding Down Operations - Following a strategic review, LianBio's Board of Directors has determined that winding down...
93 Views
2023 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe
Despite ongoing recovery and fading effect of the COVID-19, healthcare companies had varying performances in 2023. From my coverage, the top...
872 Views
China Healthcare Weekly (Dec.25) - OK Lens VBP, Angelalign, Extraordinary 2022 for Pharmaceuticals
The OK lens VBP in Hebei was the first to release detailed rules. The orthodontic material VBP result would affect Angelalign's outlook. 2022 is an...
777 Views
2022 High Conviction (China Healthcare) - Seek the Relative Certainties Out of the Uncertainties
The article analyzed the 2021 review and 2022 high conviction ideas, including the industry characteristics, the business, the core...
683 Views
Lianbio -Ads (LIAN) - Tuesday, Oct 31, 2023
The company recently sold exclusive rights to develop and commercialize mavacamten in certain areas of Asia to Bristol Myers Squibb for $350 million.
377 Views